Tribamec Duo 50 mg/ml & 1 mg/ml Oral Suspension for Sheep

Kraj: Wielka Brytania

Język: angielski

Źródło: VMD (Veterinary Medicines Directorate)

Składnik aktywny:

Ivermectin, Triclabendazole

Dostępny od:

EU Pharmaceuticals Ltd

Kod ATC:

QP54AA51

INN (International Nazwa):

Ivermectin, Triclabendazole

Forma farmaceutyczna:

Oral suspension

Typ recepty:

POM-VPS -Prescription Only Medicine – Veterinarian, Pharmacist, Suitably Qualified Person

Grupa terapeutyczna:

Sheep

Dziedzina terapeutyczna:

Endectocide

Status autoryzacji:

Authorized

Data autoryzacji:

2021-11-16

Charakterystyka produktu

Issued: November 2021
AN: 00517/2020
Page 1 of 6
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Tribamec Duo 50 mg/ml & 1 mg/ml Oral Suspension for Sheep
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE INGREDIENTS:
Triclabendazole
50 mg/ml
Ivermectin
1 mg/ml
EXCIPIENTS:
Methyl parahydroxybenzoate (E218)
1.2 mg/ml
Propyl parahydroxybenzoate
0.5 mg/ml
Benzyl alcohol
27.0 mg/ml
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oral suspension
Cream coloured aqueous oral suspension.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
For sheep over 3 months of age.
4.2
INDICATION FOR USE
Treatment of mixed trematode (fluke) and nematode or arthropod
infections due to
gastrointestinal roundworms, lungworms, liver fluke and nasal bots.
GASTROINTESTINAL NEMATODES (ADULT AND IMMATURE):
_Haemonchus contortus, Teladorsagia (Ostertagia) circumcincta,
Trichostrongylus _
_spp, Cooperia spp, Nematodirus spp_ including _ N. battus_, _
Strongyloides papillosus, _
_Oesophagostomum spp_, and adult _Chabertia ovina._
Inhibited larval stages and benzimidazole resistant strains of
_Haemonchus contortus_
and _Teladorsagia (Ostertagia) circumcincta_ are also controlled.
LIVER FLUKE (MATURE, IMMATURE AND EARLY IMMATURE STAGES DOWN TO LESS
THAN 1
WEEK OF AGE):
_Fasciola hepatica_
Issued: November 2021
AN: 00517/2020
Page 2 of 6
LUNGWORMS (ADULT AND IMMATURE):
_Dictyocaulus filaria_
NASAL BOTS (ALL STAGES):
_Oestrus ovis_
4.3
CONTRAINDICATIONS
Do not use in animals with known hypersensitivity to the active
ingredients or any of
the excipients.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices because they
increase the risk
of development of resistance and could ultimately result in
ineffective therapy:
•
Too frequent and repeated use of anthelmintics from the same class,
over an extended period of time.
•
Underdosing which may be due to underestimation of bodyweight,
misadministration of the product or lack of calibration of the dosing
de